New Releases from NCBI BookshelfBelzutifan (Welireg): Indication: For the treatment of adult patients with advanced renal cell carcinoma following a programmed death receptor-1 or programmed death-ligand 1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor: Reimbursement Recommendation [Internet].​Belzutifan (Welireg): Indication: For the treatment of adult patients with advanced renal cell carcinoma following a programmed death receptor-1 or programmed death-ligand 1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor: Reimbursement Recommendation [Internet].